

Yuchan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6756787/publications.pdf>

Version: 2024-02-01

19
papers

344
citations

933447

10
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

567
citing authors

#	ARTICLE	IF	CITATIONS
1	Interaction with Cyclin H/Cyclin-dependent Kinase 7 (CCNH/CDK7) Stabilizes C-terminal Binding Protein 2 (CtBP2) and Promotes Cancer Cell Migration. <i>Journal of Biological Chemistry</i> , 2013, 288, 9028-9034.	3.4	67
2	ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas. <i>Experimental Cell Research</i> , 2015, 335, 216-223.	2.6	46
3	Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. <i>Leukemia Research</i> , 2015, 39, 1428-1436.	0.8	39
4	Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. <i>Experimental Cell Research</i> , 2016, 346, 157-166.	2.6	34
5	The role of the orphan G protein-coupled receptor 37 (GPR37) in multiple myeloma cells. <i>Leukemia Research</i> , 2014, 38, 225-235.	0.8	27
6	Expression of CDC5L is associated with tumor progression in gliomas. <i>Tumor Biology</i> , 2016, 37, 4093-4103.	1.8	22
7	CDK14 involvement in proliferation migration and invasion of esophageal cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 681-681.	1.7	20
8	Cell adhesion induces overexpression of chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L) and contributes to cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma cells. <i>Leukemia Research</i> , 2016, 47, 54-62.	0.8	16
9	Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR). <i>Leukemia Research</i> , 2014, 38, 955-963.	0.8	15
10	Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma. <i>International Journal of Biological Macromolecules</i> , 2015, 81, 809-817.	7.5	14
11	CAM-DR: Mechanisms, Roles and Clinical Application in Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 698047.	3.7	10
12	DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas. <i>Leukemia Research</i> , 2016, 50, 104-111.	0.8	7
13	Low expression of cyclic amp response element modulator-1 can increase the migration and invasion of esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2013, 34, 3649-3657.	1.8	6
14	Expression of far upstream element binding protein 1 in B-cell non-Hodgkin lymphoma is correlated with tumor growth and cell-adhesion mediated drug resistance. <i>Molecular Medicine Reports</i> , 2016, 14, 3759-3768.	2.4	5
15	Overexpression of activator of G-protein signaling 3 decreases the proliferation of esophageal squamous cell carcinoma. <i>Pathology Research and Practice</i> , 2015, 211, 449-455.	2.3	4
16	Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM). <i>BMC Cancer</i> , 2019, 19, 1269.	2.6	4
17	Î²-TrCP1 promotes cell proliferation via TNF-dependent NF-Î²B activation in diffuse large B cell lymphoma. <i>Cancer Biology and Therapy</i> , 2020, 21, 241-247.	3.4	3
18	Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma. <i>Oncology Letters</i> , 2019, 17, 2993-3000.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Role of Apg-1 in HSF1 activation and bortezomib sensitivity in myeloma cells. <i>Experimental Hematology</i> , 2020, 81, 50-59.	0.4	2